share_log

信達生物：截至2024年6月30日止六個月中期業績公告

INNOVENT BIO: INTERIM RESULTS ANNOUNCEMENTFOR THE SIX MONTHS ENDED 30 JUNE 2024

HKEX ·  Aug 28 18:00

Summary by Futu AI

信達生物公布2024年上半年業績，收入增長46.3%，期內虧損擴大至人民幣392.6百萬元。信達生物製藥（「信達生物」）公佈截至2024年6月30日止六個月的未經審核中期業績。期內，公司實現來自客戶合約的收入人民幣3,952.3百萬元，較去年同期增長46.3%。毛利率由去年同期的81.3%提升至82.9%，反映出產量增加及生產成本優化。研發開支增至人民幣1,399.4百萬元，較去年同期增加51.6%，主要用於支持公司可持續增長及全球創新戰略目標。銷售及市場推廣開支為人民幣1,879.4百萬元，佔總收入的47.6%。期內虧損為人民幣392.6百萬元，較去年同期的人民幣139.1百萬元增加253.5百萬元，主要由於非現金項目的淨匯兌收益減少及一次性所得稅抵免減少所致。
信達生物公布2024年上半年業績，收入增長46.3%，期內虧損擴大至人民幣392.6百萬元。信達生物製藥（「信達生物」）公佈截至2024年6月30日止六個月的未經審核中期業績。期內，公司實現來自客戶合約的收入人民幣3,952.3百萬元，較去年同期增長46.3%。毛利率由去年同期的81.3%提升至82.9%，反映出產量增加及生產成本優化。研發開支增至人民幣1,399.4百萬元，較去年同期增加51.6%，主要用於支持公司可持續增長及全球創新戰略目標。銷售及市場推廣開支為人民幣1,879.4百萬元，佔總收入的47.6%。期內虧損為人民幣392.6百萬元，較去年同期的人民幣139.1百萬元增加253.5百萬元，主要由於非現金項目的淨匯兌收益減少及一次性所得稅抵免減少所致。
innovent bio announced its performance for the first half of 2024, with an increase in revenue of 46.3% and a widening loss of 392.6 million yuan. innovent bio pharmaceuticals (innovent bio) announced its unaudited interim performance for the six months ended June 30, 2024. During the period, the company achieved revenue of 395.23 million yuan from customer contracts, an increase of 46.3% compared to the same period last year. The gross margin increased from 81.3% in the same period last year to 82.9%, reflecting increased production and optimized production costs. Research and development expenses increased to 1399.4 million yuan, a 51.6% increase from the same period last year, mainly to support the company's sustainable growth and global innovation strategic goals. Sales and marketing expenses were 1,879.4 million yuan, accounting for 47.6% of total revenue. The loss for the period was 392.6 million yuan, an increase of 253.5 million yuan from the same period last year, mainly due to a decrease in non-cash item net exchange gains and a decrease in one-time income tax deductions.
innovent bio announced its performance for the first half of 2024, with an increase in revenue of 46.3% and a widening loss of 392.6 million yuan. innovent bio pharmaceuticals (innovent bio) announced its unaudited interim performance for the six months ended June 30, 2024. During the period, the company achieved revenue of 395.23 million yuan from customer contracts, an increase of 46.3% compared to the same period last year. The gross margin increased from 81.3% in the same period last year to 82.9%, reflecting increased production and optimized production costs. Research and development expenses increased to 1399.4 million yuan, a 51.6% increase from the same period last year, mainly to support the company's sustainable growth and global innovation strategic goals. Sales and marketing expenses were 1,879.4 million yuan, accounting for 47.6% of total revenue. The loss for the period was 392.6 million yuan, an increase of 253.5 million yuan from the same period last year, mainly due to a decrease in non-cash item net exchange gains and a decrease in one-time income tax deductions.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Heat List
    US
    SymbolLatest Price% Chg

    No Data

    Hot News
    Updated